Randomized Trialhigh evidence
Low-dose ticagrelor combined with aspirin for preventing early neurological deterioration in patients with high-risk non-disabling ischemic cerebrovascular events: a multicenter, prospective, randomized, open-label, clinical trial.
Journal of neurology·September 7, 2026·PMID 42704480
Why it mattersClopidogrel's efficacy is limited by CYP2C19 polymorphisms common in Asian populations, and rapid genotyping is often unavailable. This trial offers a practical alternative that avoids genotyping and reduces early deterioration, a key predictor of poor stroke outcomes.
The papers that matter, first.
MedLit ranks the medical literature into a specialty feed with concise summaries, evidence-aware triage, and visual takeaways.
§
MedLit · Evidence, Distilled